551 related articles for article (PubMed ID: 20816042)
1. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
Kane JM; Yang R; Youakim JM
Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
Calabrese JR; Ketter TA; Youakim JM; Tiller JM; Yang R; Frye MA
J Clin Psychiatry; 2010 Oct; 71(10):1363-70. PubMed ID: 20673554
[TBL] [Abstract][Full Text] [Related]
4. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
[TBL] [Abstract][Full Text] [Related]
5. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial.
Bobo WV; Woodward ND; Sim MY; Jayathilake K; Meltzer HY
Schizophr Res; 2011 Aug; 130(1-3):106-13. PubMed ID: 21641776
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
Krystal AD; Harsh JR; Yang R; Rippon GA; Lankford DA
J Clin Psychiatry; 2010 Jan; 71(1):32-40. PubMed ID: 20051221
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.
Arbabi M; Bagheri M; Rezaei F; Ahmadi-Abhari SA; Tabrizi M; Khalighi-Sigaroudi F; Akhondzadeh S
Psychopharmacology (Berl); 2012 Apr; 220(3):591-8. PubMed ID: 21947320
[TBL] [Abstract][Full Text] [Related]
8. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.
Freudenreich O; Henderson DC; Macklin EA; Evins AE; Fan X; Cather C; Walsh JP; Goff DC
J Clin Psychiatry; 2009 Dec; 70(12):1674-80. PubMed ID: 19689921
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial.
Calabrese JR; Frye MA; Yang R; Ketter TA;
J Clin Psychiatry; 2014 Oct; 75(10):1054-61. PubMed ID: 25099397
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
11. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.
Saavedra-Velez C; Yusim A; Anbarasan D; Lindenmayer JP
J Clin Psychiatry; 2009 Jan; 70(1):104-12. PubMed ID: 19026265
[TBL] [Abstract][Full Text] [Related]
12. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M
Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
15. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Goff DC; Lamberti JS; Leon AC; Green MF; Miller AL; Patel J; Manschreck T; Freudenreich O; Johnson SA
Neuropsychopharmacology; 2008 Feb; 33(3):465-72. PubMed ID: 17487227
[TBL] [Abstract][Full Text] [Related]
16. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
17. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
19. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
Lohr JB; Liu L; Caligiuri MP; Kash TP; May TA; Murphy JD; Ancoli-Israel S
Schizophr Res; 2013 Oct; 150(1):289-96. PubMed ID: 23938173
[TBL] [Abstract][Full Text] [Related]
20. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
